Special meeting of stockholders to vote on Merger to take place on May 28, 2025 WALTHAM, Mass., May 13, 2025 (GLOBE NEWSWIRE) ...

UNLOXCYT (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma Special meeting of stockholders to vote on Merge ...

The Feinstein Institutes for Medical Research has selected Jeffery W. Kelly, PhD, from Scripps Research, to receive the 12th annual Ross Prize in Molecular Medicine. Dr. Kelly is recognized for his ...

Q1 2025 Earnings Call Transcript May 15, 2025 Operator: Thank you for standing by. And welcome to Invivyd’s First Quarter ...

In briefing documents released by the FDA reviewer, the agency has made it clear that the Chinese clinical results filed in support of the PD-1 inhibitor do not meet the criteria for foreign data ...

Prostaglandin E2 (PGE2), a bioactive lipid derived from arachidonic acid, mediates a broad range of physiological processes ...

Leronlimab increased PD-L1 in patients with triple-negative breast cancer, potentially making cold tumors responsive to ...

Scientists are aiming to determine the composition and topology of physiological Ashwell-Morell receptor ligands. Their findings will help uncover the receptor's still-hidden secrets.

BACKGROUND: Exercise improves functional outcomes in patients with diabetic cardiomyopathy (DiaCM). The molecular mechanism ...

Katie Falzone; Senior Vice President, Finance; Invivyd Inc. Marc Elia; Independent Chairman of the Board; Invivyd Inc. Tim Lee; Chief Commercial Officer; Invivyd Inc ...

iTeos Therapeutics announced that the GALAXIES Lung-201 Phase 2 trial, assessing the combination of belrestotug and dostarlimab for lung cancer, did not meet the criteria for clinically meaningful ...